TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH UPADACITINIB RESULTS IN THE COORDINATED INHIBITION OF TYPE 1 IFN-RELATED BIOMARKERS: BIOMARKER ANALYSIS OF THE M19130 (SLEEK) PHASE 2 STUDY

被引：2
|
作者：
Gaudreau, M. C. [1 ]
Fann, J. [1 ]
Contrepois, S. [1 ]
Friedman, A. [1 ]
Sornasse, T. [1 ]
Merrill, J. T. [2 ]
机构：
[1] AbbVie, Rheumatol, N Chicago, IL USA
[2] Oklahoma Med Res Fdn, Arthrit Clin Immunol Program, Oklahoma City, OK USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Cytokines and chemokines; Biomarkers; Systemic lupus; erythematosus;
D O I：
10.1136/annrheumdis-2023-eular.4002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1133
引用
收藏
页码：894 / 895
页数：2
相关论文
共 10 条
  • [1] Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell-related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
    Gaudreau, Marie-Claude
    Fann, James
    Friedman, Alan
    Sornasse, Thierry
    Merrill, Joan
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2940 - 2941
  • [2] EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY
    Furie, R.
    Werth, V.
    Milliman, E.
    Ferber, K.
    Casey, F.
    Brown, R.
    Raitcheva, D.
    Zoghbi, J.
    Graham, D.
    Kong, G.
    Lahoud, Y.
    Franchimont, N.
    Barbey, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1453 - 1454
  • [3] Litifilimab modulates Type 1 interferon (IFN) biomarkers in patients with cutaneous lupus erythematosus (CLE): Result of the LILAC Part B Phase 2 study
    Werth, V. P.
    Furie, R. A.
    Milliman, E.
    Ferber, K.
    Casey, F.
    Brown, R.
    Raitcheva, D.
    Zoghbi, J.
    Graham, D.
    Kong, G.
    Lahoud, Y.
    Franchimont, N.
    Barbey, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S101 - S101
  • [4] Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus
    Wu, Chun
    Hu, Yanhua
    Crow, Mary K.
    Saxena, Amit
    Arriens, Cristina
    Hobar, Coburn
    Coles, Adrian
    Catlett, Ian M.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1699 - 1701
  • [5] SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EPRATUZUMAB IN JAPANESE PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PHASE 1/2 STUDY
    Yamamoto, J.
    Lledo-Garcia, R.
    Tsuru, T.
    Tanaka, Y.
    Koike, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 526 - 526
  • [6] Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study
    Tsuru, Tomomi
    Tanaka, Yoshiya
    Kishimoto, Mitsumasa
    Saito, Kazuyoshi
    Yoshizawa, Seiji
    Takasaki, Yoshinari
    Miyamura, Tomoya
    Niiro, Hiroaki
    Morimoto, Shinji
    Yamamoto, Junichi
    Lledo-Garcia, Rocio
    Shao, Jing
    Tatematsu, Shuichiro
    Togo, Osamu
    Koike, Takao
    MODERN RHEUMATOLOGY, 2016, 26 (01) : 87 - 93
  • [7] TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
    Furie, Richard
    Bomba, Darrin
    Dall'era, Maria
    Prieto, Massiel
    Anderl, Janet
    Wang, Jinhai
    Kirk, Christopher
    Goel, Niti
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 776 - 777
  • [8] Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
    van Vollenhoven, Ronald
    Hahn, Bevra H.
    Tsokos, George C.
    Wagner, Carrie
    Lipsky, Peter
    Hsu, Benjamin
    Chevrier, Marc
    Gordon, Robert
    Lo, Kim Hung
    Triebel, Manon
    Fei, Kaiyin
    Rose, Shawn
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY
    van Vollenhoven, Ronald
    Tsokos, George
    Gordon, Robert
    Lo, Kim Hung
    Gregan, Y. Irene
    Fei, Kaiyin
    Rose, Shawn
    Hahn, Bevra H.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 91 - 91
  • [10] Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2
    Armstrong, April W.
    Liu, Yan
    Li, Nan
    Reich, Kristian
    Foley, Peter
    Li, Shu
    Fakharzadeh, Steven
    Papp, Kim A.
    Han, Chenglong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB128 - AB128
1